Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2389-2393

  Tran, Thien Duc ^a   Pryde, David C ^a   Jones, Peter ^a   Adam, Fiona M ^a   Benson, Neil ^a   Bish, Gerwyn ^a   Calo, Frederick ^a   Ciaramella, Guiseppe ^a   Dixon, Rachel ^b   Duckworth, Jonathan ^a   Fox, David N A ^a   Hay, Duncan A ^a   Hitchin, James ^b   Horscroft, Nigel ^a   Howard, Martin ^a   Gardner, Iain ^a   Jones, Hannah M ^a   Laxton, Carl ^a   Parkinson, Tanya ^a   Parsons, Gemma ^a   Proctor, Katie ^a   Smith, Mya C ^a   Smith, Nicholas ^a   Thomas, Amy ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b SRG   (United Kingdom)

Author keywords

Aldehyde oxidase; HCV; Interferon inducer; TLR7 agonist

Indexed keywords

TETRAHYDROPYRAN DERIVATIVE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HEPATITIS C; HUMAN; HUMAN CELL; INTERFERON INDUCTION; LIVER MICROSOME; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; HEPACIVIRUS; MICE; MODELS, ANIMAL; PURINES; RATS; RNA VIRUS INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 7;

HEPATITIS C VIRUS;

EID: 79953280471     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.092     Document Type: Article

References (20)

1. World Health Organisation. Weekly Epidemiological Record, 1999, No 49.
2. Q.M. Wang, and B.A. Heinz Prog. Drug Res. 55 2000 1
3. C.A. Janeway, and R. Medzhitoov Annu. Rev. Immunol. 20 2002 197
4. B. Beutler Nature 430 2004 257
5. L.A. O'Neill Science 303 2004 1481
6. J. Lee, T. Chuang, V. Redecke, L. She, P.M. Pitha, D.A. Carson, E. Raz, and H.B. Cottam Proc. Natl. Acad. Sci. U.S.A. 100 2003 6646
7. H. Tran, G. Moreno, and S. Shumack Expert Opin. Pharmacother. 5 2004 427
8. R.L. Miller, T.C. Meng, and M.A. Tomai Drug News Perspect. 21 2008 69
9. D.H. Dockrell, and G.R. Kinghorn J. Antimicrob. Chemother. 48 2001 751
10. A. Kurimoto, T. Tobe, S. Ichii, Y. Isobe, M. Tobe, H. Ogita, H. Takaku, H. Sajiki, K. Hirota, and H. Kawakami Bioorg. Med. Chem. 12 2004 1091
11. Pryde, D. C.; Tran, T. D.; Jones, P.; Parsons, G. C.; Bish, G.; Adam, F. M.; Smith, M. C.; Hay, D.; Paradowski, M.; Proctor, K. J. W.; Parkinson, T.; Laxton, C.; Fox, D. N. A.; Horscroft, N. J.; Ciaramella, G.; Jones, H. M.; Duckworth, J.; Benson, N.; Harrison, A.; Webster, R. Med. Chem. Commun. 2011, doi:10.1039/C0MD00197J.
12. Bish, G.; Adam, F. M.; Calo, F.; Carr, C.; Castro, N.; Hay, D.; Hodgson, P.; Jones, P.; Knight, C.; Parsons, G.; Proctor, K. J. W.; Pryde, D. C.; Rota, F.; Smith, N.; Tran, T. D. Org. Process Res. Dev., in press.
13. A. Thomas, C. Laxton, J. Rodman, N. Myangar, N. Horscroft, and T. Parkinson Antimicrob. Agents Chemother. 51 2007 2969
14. D.C. Pryde, D. Dalvie, Q. Hu, P. Jones, R.S. Obach, and T.D. Tran J. Med. Chem. 53 2010 8441
15. Data not shown.
16. J.E. Milne, and S.L. Buchwald J. Am. Chem. Soc. 126 2004 13028
17. N. Benson, J. de Jongh, J.D. Duckworth, H.M. Jones, H.E. Pertinez, J.K. Rawal, T.J. van Steeg, and P.H. Van der Graaf Antimicrob. Agents Chemother. 54 2010 1179
18. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Science 282 1998 103
19. H.M. Jones, N. Parrott, K. Jorga, and T. Lave Clin. Pharmacokinet. 45 2006 511
20. The potency discrepancy for compound 1 between this article and Ref. 9 is due to the use of different assay formats. In this article, a co-culture assay in a 384-well plate format was used compared to a 96-well plate format used in Ref. 9.